↑Sweeney C, Dudhipala N, Thakkar R, Mehraj T, Marathe S, Gul W, etal. (October 2021). "Effect of surfactant concentration and sterilization process on intraocular pressure-lowering activity of Δ9-tetrahydrocannabinol-valine-hemisuccinate (NB1111) nanoemulsions". Drug Delivery and Translational Research. 11 (5): 2096–2107. doi:10.1007/s13346-020-00871-9. PMID33169348.
↑Sweeney C, Dudhipala N, Thakkar R, Mehraj T, Marathe S, Gul W, etal. (March 2022). "Impact of mucoadhesive agent inclusion on the intraocular pressure lowering profile of Δ9-tetrahydrocannabinol-valine-hemisuccinate loaded nanoemulsions in New Zealand white rabbits". International Journal of Pharmaceutics. 616 121564. doi:10.1016/j.ijpharm.2022.121564. PMID35151817.
↑US 8809261,Elsohly MA, Gul W, Repka MA, Majumdar S,"Compositions containing delta-9-THC-amino acid esters and process of preparation.",issued 19 August 2014, assigned to ElSohly Laboratories, Inc.
↑WO 2020/215164,Hsu E, Kumar U, Kumar R,"Compositions and methods for use of cannabinoids for neuroprotection",published 29 October 2020, assigned to Inmed Pharmaceuticals Inc.